AI Decision Support for Prostate MRI
Pi™ is a CE-marked Class IIb AI tool that analyses multi-parametric prostate MRI (T2, DWI, DCE). It automatically segments the gland and lesions, calculates volumes, suggests PI-RADS–aligned risk scores, and delivers a clear, structured report ready for biopsy planning or surveillance.
Key benefits
- 95% sensitivity for clinically significant prostate cancer in the PAIR-1 multicentre study
- Reduces subjective variability and supports same-day biopsy decisions
- Generates 3-D lesion maps and volumetric data in under 10 minutes
- Compatible with existing PACS viewers—no extra worklists
Details
- Regulatory: CE-MDR Class IIb | FDA 510(k) submission under review
- Applications: Urology, Oncology, Radiology
- Modality: MRI (T2 / DWI / DCE)
- Body part: Prostate
Clinical evidence
- PAIR-1 Study (8 UK hospitals, 2023): 95% sensitivity, 67% specificity for csPCa detection.
- NHS rollout (Innovate UK, 2024): demonstrated time savings and biopsy-planning accuracy across multiple trusts.
For the latest clinical evidence and updates, visit the company’s official website: https://www.lucidamedical.com/
Ask K2AI how Lucida Medical’s Pi™ can bring faster, more consistent prostate-MRI analysis to your radiology workflow.
בניית אתרים JUNAMI